Enhanced expression of hypersensitive α4* nAChR in adult mice increases the loss of midbrain dopaminergic neurons

FASEB Journal

Volumn 20, Issue 7, 2006, Pages 935-946

  Schwarz, Johannes ^a   Schwarz, Sigrid C ^a   Dorigo, Oliver ^b,c   Stützer, Alexandra ^a   Wegner, Florian ^a   Labarca, Cesar ^d   Deshpande, Purnima ^d   Gil, Jose S ^b,c   Berk, Arnold J ^b,c   Lester, Henry A ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d 156 29 Caltech ^*

Author keywords

Cholinergic excitotoxicity; Helper dependent adenovirus; Knock in mouse; Nicotinic receptor; Parkinson's disease; Substantia nigra

Indexed keywords

AMPHETAMINE; CRE RECOMBINASE; NEOMYCIN; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4; DOPAMINE; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA4 SUBUNIT;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CELL DEATH; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; GENE CASSETTE; GENE TRANSFER; GENETIC MODEL; GENOMICS; INTRON; LOCOMOTION; MALE; MESENCEPHALON; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; SUBSTANTIA NIGRA; TRANSGENIC ANIMAL;

ADENOVIRIDAE; ANIMALIA;

ADENOVIRIDAE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL DEATH; DOPAMINE; GENE EXPRESSION REGULATION; LOCOMOTION; MICE; NEURONS; RECEPTORS, NICOTINIC; SUBSTANTIA NIGRA;

EID: 33744454692     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.05-5497com     Document Type: Article

References (52)

1. Arroyo-Jiminez, M. M., Bourgeois, J. P., Marubio, L. M., Le Sourd, A. M., Ottersen, O. P., Rinvik, E., Fairen, A., and Changeux, J. P. (1999) Ultrastructural localization of the α4 subunit of the neuronal acetylcholine nicotinic receptor in the rat substantia nigra. J. Neurosci. 19, 6475-6487
2. Luo, S., Kulak, J., Cartier, G., Jacobsen, R., Yoshikami, D., Olivera, B., and McIntosh, J. (1998) Alpha-conotoxin AuIB selectively blocks α3β4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release. J. Neurosci. 18, 8571-8579
3. Pidoplichko, V., DeBiasi, M., Williams, J., and Dani, J. (1997) Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390, 401-404
4. Nisell, M., Nomikos, G. G., Hertel, P., Panagis, G., and Svensson, T. H. (1996) Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. Synapse 22, 369-381
5. Takaki, T. (1995) [Chronic treatment with nicotine enhances the sensitivity of dopamine autoreceptors that modulate dopamine release from the rat striatum]. Nihon Shinkei Seishin Yakurigaku Zasshi 15, 335-344
6. Fung, Y. K., and Lau, Y. S. (1989) Effect of nicotine pretreatment on striatal dopaminergic system in rats. Pharmacol. Biochem. Behav. 32, 221-226
7. Orb, S., Wieacker, J., Labarca, C., Fonck, C., Lester, H. A., and Schwarz, J. (2004) Knockin mice with Leu9'Ser alpha4-nicotinic receptors: substantia nigra dopaminergic neurons are hypersensitive to agonist and lost postnatally. Physiol. Genomics 18, 299-307
8. Labarca, C., Schwarz, J., Deshpande, P., Schwarz, S. C., Nowak, M. W., Fonck, C., Naashmi, R., Kofuji, P., Dang, H., Shi, W., Fidan, M., Khakh, B. S., Chen, Z., Bowers, B. J., Boulter, J., Wehner, J. M., and Lester, H. A. (2001) Point mutant mice with hypersensitive α4 nicotinic receptors show dopaminergic deficits and increased anxiety. Proc. Natl. Acad. Sci. USA 98, 2786-2791
9. Post, L. E. (2002) Selectively replicating adenoviruses for cancer therapy: an update on clinical development. Curr. Opin. Invest. Drugs 3, 1768-1772
10. Warren, R. S., and Kirn, D. H. (2002) Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond. Surg. Oncol. Clin. N. Am. 11, 571-588, vi
11. Breyer, B., Jiang, W., Cheng, H., Zhou, L., Paul, R., Feng, T., and He, T. C. (2001) Adenoviral vector-mediated gene transfer for human gene therapy. Curr. Gene. Ther. 1, 149-162
12. Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G. P., Wilson, J. M., and Batshaw, M. L. (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80, 148-158
13. Lowenstein, P. R., Thomas, C. E., Umana, P., Gerdes, C. A., Verakis, T., Boyer, O., Tondeur, S., Klatzmann, D., and Castro, M. G. (2002) High-capacity, helper-dependent, "gutless" adenoviral vectors for gene transfer into brain. Methods Enzymol. 346, 292-311
14. Fonck, C., Nashmi, R., Deshpande, P., Damaj, M. I., Marks, M. J., Riedel, A., Schwarz, J., Collins, A. C., Labarca, C., and Lester, H. A. (2003) Increased sensitivity to agonist-induced seizures, straub tail, and hippocampal theta rhythm in knock-in mice carrying hypersensitive alpha 4 nicotinic receptors. J. Neurosci. 23, 2582-2590
15. Parks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A., and Graham, F. L. (1996) A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA 93, 13565-13570
16. Dorigo, O., Gil, J. S., Gallaher, S. D., Tan, B. T., Castro, M. G., Lowenstein, P. R., Calos, M. P., and Berk, A. J. (2004) Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. J. Virol. 78, 6556-6566
17. Kovoor, A., Seyffarth, P., Ebert, J., Barghshoon, S., Chen, C.-K., Schwarz, S., Axelrod, J. D., Cheyette, B. N. R., Simon, M. I., Lester, H. A., and Schwarz, J. (2005) D2 dopamine receptors colocalize RGS9 2 via the RGS9 DEP domain and RGS9 knockout mice develop dyskinesias associated with dopamine pathways. J. Neurosci. In press
18. Marazziti, D., Golini, E., Mandillo, S., Magrelli, A., Witke, W., Matteoni, R., and Tocchini-Valentini, G. P. (2004) Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor. Proc. Natl. Acad. Sci. USA 101, 10,189-10,194
19. Kochanek, S., Clemens, P. R., Mitani, K., Chen, H. H., Chan, S., and Caskey, C. T. (1996) A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. USA 93, 5731-5736
20. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., and Mucke, L. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269
21. Sauer, H., and Oertel, W. H. (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59, 401-415
22. Triarhou, L. C., Norton, J., and Ghetti, B. (1988) Mesencephalic dopamine cell deficit involves areas A8, A9 and A10 in weaver mutant mice. Exp. Brain Res. 70, 256-265
23. Sapolsky, R. M. (2003) Neuroprotective gene therapy against acute neurological insults. Nat. Rev. Neurosci. 4, 61-69
24. Hsich, G., Sena-Esteves, M., and Breakefield, X. O. (2002) Critical issues in gene therapy for neurologic disease. Hum. Gene Ther. 13, 579-604
25. Dobson, A. T., Margolis, T. P., Sedarati, F., Stevens, J. G., and Feldman, L. T. (1990) A latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in mouse neurons. Neuron 5, 353-360
26. Andersen, J. K., Garber, D. A., Meaney, C. A., and Breakefield, X. O. (1992) Gene transfer into mammalian central nervous system using herpes virus vectors: extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter. Hum. Gene Ther. 3, 487-499
27. Nabel, G. J. (1999) Development of optimized vectors for gene therapy. Proc. Natl. Acad. Sci. USA 96, 324-326
28. Ehrengruber, M. U. (2002) Alphaviral vectors for gene transfer into neurons. Mol. Neurobiol. 26, 183-201
29. Lowenstein, P. R., and Castro, M. G. (2003) Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences. Gene Ther. 10, 946-954
30. Millecamps, S., Kiefer, H., Navarro, V., Geoffroy, M. C., Robert, J. J., Finiels, F., Mallet, J., and Barkats, M. (1999) Neuronrestrictive silencer elements mediate neuron specificity of adenoviral gene expression. Nat. Biotechnol. 17, 865-869
31. Navarro, V., Millecamps, S., Geoffroy, M. C., Robert, J. J., Valin, A., Mallet, J., and Gal La Salle, G. L. (1999) Efficient gene transfer and long-term expression in neurons using a recombinant adenovirus with a neuron-specific promoter. Gene Ther. 6, 1884-1892
32. Ideguchi, M., Kajiwara, K., Yoshikawa, K., Uchida, T., and Ito, H. (2000) Local adenovirus-mediated CTLA4-immunoglobulin expression suppresses the immune responses to adenovirus vectors in the brain. Neuroscience 95, 217-226
33. Cartmell, T., Southgate, T., Rees, G. S., Castro, M. G., Lowenstein, P. R., and Luheshi, G. N. (1999) Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain. J. Neurosci. 19, 1517-1523
34. Kochanek, S. (1999) High-capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum. Gene Ther. 10, 2451-2459
35. Kochanek, S., Schiedner, G., and Volpers, C. (2001) High-capacity 'gutless' adenoviral vectors. Curr. Opin. Mol. Ther. 3, 454-463
36. Morsy, M. A., and Caskey, C. T. (1999) Expanded-capacity adenoviral vectors-the helper-dependent vectors. Mol. Med. Today 5, 18-24
37. Schiedner, G., Hertel, S., Johnston, M., Biermann, V., Dries, V., and Kochanek, S. (2002) Variables affecting in vivo performance of high-capacity adenovirus vectors. J. Virol. 76, 1600-1609
38. Morsy, M. A., Gu, M., Motzel, S., Zhao, J., Lin, J., Su, Q., Allen, H., Franlin, L., Parks, R. J., Graham, F. L., Kochanek, S., Bett, A. J., and Caskey, C. T. (1998) An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. USA 95, 7866-7871
39. Peltekian, E., Garcia, L., and Danos, O. (2002) Neurotropism and retrograde axonal transport of a canine adenoviral vector: a tool for targeting key structures undergoing neurodegenerative processes. Mol. Ther. 5, 25-32
40. Soudais, C., Skander, N., and Kremer, E. J. (2004) Long-term in vivo transduction of neurons throughout the rat CNS using novel helper-dependent CAV-2 vectors. FASEB J. 18, 391-393
41. Worgall, S., Leopold, P. L., Wolff, G., Ferris, B., Van Roijen, N., and Crystal, R. G. (1997) Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum. Gene Ther. 8, 1675-1684
42. Tapper, A., McKinney, S., Nashmi, R., Schwarz, J., Deshpande, P., Labarca, C., Whiteaker, P., Collins, A., and Lester, H. (2004) Nicotine action on α4* receptors: sufficient for reward, tolerance and sensitization. Science 306, 1029-1032
43. Iribe, Y., Moore, K., Pang, K. C., and Tepper, J. M. (1999) Subthalamic stimulation-induced synaptic responses in substantia nigra pars compacta dopaminergic neurons in vitro. J. Neurophysiol. 82, 925-933
44. Futami, T., Takakusaki, K., and Kitai, S. T. (1995) Glutamatergic and cholinergic inputs from the pedunculopontine tegmental nucleus to dopamine neurons in the substantia nigra pars compacta. Neurosci. Res. 21, 331-342
45. Breit, S., Bouali-Benazzouz, R., Benabid, A. L., and Benazzouz, A. (2001) Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal activity of the pedunculopontine nucleus, which is reversed by the lesion of the subthalamic nucleus in the rat. Eur. J. Neurosci. 14, 1833-1842
46. Takada, M., Matsumura, M., Kojima, J., Yamaji, Y., Inase, M., Tokuno, H., Nambu, A., and Imai, H. (2000) Protection against dopaminergic nigrostriatal cell death by excitatory input ablation. Eur. J. Neurosci. 12, 1771-1780
47. Klein, R. L., King, M. A., Hamby, M. E., and Meyer, E. M. (2002) Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum Gene Ther 13, 605-612
48. Kirik, D., Annett, L. E., Burger, C., Muzyczka, N., Mandel, R. J., and Bjorklund, A. (2003) Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 100, 2884-2889
49. Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., Mandel, R. J., and Bjorklund, A. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780-2791
50. Lo Bianco, C., Ridet, J. L., Schneider, B. L., Deglon, N., and Aebischer, P. (2002) alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 99, 10,813-10,818
51. van der Putten, H., Wiederhold, K. H., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W. P., Ruegg, M. A., Lin, S., Caroni, P., Sommer, B., Tolnay, M., and Bilbe, G. (2000) Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20, 6021-6029
52. Storch, A., Schrattenholz, A., Cooper, J. C., Abdel Ghani, E. M., Gutbrod, O., Weber, K. H., Reinhardt, S., Lobron, C., Hermsen, B., Soskic, V., et al. (1995) Physostigmine, galanthamine and codeine act as 'noncompetitive nicotinic receptor agonists' on clonal rat pheochromocytoma cells. Eur. J. Pharmacol. 290, 207-219